CPC Issues Letter to Fellow XWELL, Inc. Shareholders Revealing Intention Behind Recent Schedule 13D Filing & Lawsuit Against Entrenched Board of Directors
24 July 2024 - 11:00PM
Today, CPC Pain & Wellness SPV, LLC (“CPC”), a
significant XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”)
shareholder that beneficially owns 394,200 or 9.42% of XWELL’s
outstanding shares, issued the below letter to its fellow
shareholders. The letter informs shareholders of CPC’s recent
lawsuit filing against the incumbent members of XWELL’s Board of
Directors for breach of their fiduciary duties and for the Board’s
wrongful and inequitable efforts to prevent CPC from nominating a
competing slate of directors and consequently denying shareholders
the opportunity to choose who they elect to XWELL’s Board at the
upcoming annual shareholder meeting. In its letter, CPC details how
current Board members have personally benefited from XWELL while
overseeing an astounding decline in XWELL shareholder value and
substantial net losses. CPC also shares in the below letter its
vision for restoring and maximizing shareholder value.
The full text of CPC’s letter to fellow XWELL
shareholders is below.
July 24, 2024
Dear Fellow Shareholders:
On Friday, July 19, 2024, CPC Pain &
Wellness SPV, LLC (“CPC”) filed suit against incumbent members of
XWELL’s Board of Directors (the “Board”), Chairman Bruce T.
Bernstein and directors Michael Lebowitz, Robert Weinstein, Gaëlle
Wizenberg, and Scott R. Milford (collectively, the “Entrenched
Directors”), for, among other reasons, breach of their fiduciary
duties and unlawful, unenforceable, and inequitable application of
XWELL’s bylaws to reject CPC’s notice of intent to propose its own
slate of directors for election at the 2024 annual shareholder
meeting. This rejection by the Entrenched Directors prohibits you,
our fellow shareholders, from having any other choice beyond the
slate of incumbent directors, who through negligence, self-interest
and complacency have decimated the value of the Company in which
you are invested.
CPC—which beneficially owns 394,200 XWELL shares
or, based on the most recent practicable information on XWELL’s
outstanding share numbers, 9.42% of outstanding XWELL shares—was
compelled to file suit when the named Entrenched Directors
improperly and inequitably invoked an advance notice bylaw
provision included in XWELL’s Third Amended and Restated Bylaws
(the “Bylaws”) to prevent any reasonable opportunity for CPC to
nominate individuals to stand for election to the Board at the not
yet scheduled 2024 XWELL annual shareholder meeting. At 9:00 p.m.
(EDT) on June 21, 2024, the Entrenched Directors used the Bylaws as
a sword to unlawfully and inequitably reject CPC’s director
nomination notice, demanding a response—with less than 48 hours’
notice—by “close of business” on Sunday, June 23, 2024. CPC
provided a thorough response by the suggested deadline only to then
have XWELL once again unreasonably reject CPC’s nominations—citing
pretextual, inaccurate and nonexistent deficiencies—and, this time,
disallowing CPC to further respond to correct any perceived
deficiencies. Through these actions, it is evident that the
Entrenched Directors intend to embed themselves in office at all
costs by preventing XWELL’s shareholders from nominating a
competing slate of director candidates—ultimately denying XWELL
shareholders the opportunity to choose who they elect to the Board
at the annual meeting of shareholders later this year.
The Entrenched Directors have good reason to
want to insulate themselves from shareholder opinions and votes,
having personally benefited while overseeing an astounding decline
in XWELL shareholder value and substantial net losses. On February
8, 2016—the day Bernstein joined the Board—the closing price of
XWELL’s common stock was $1,788 per share (accounting for
subsequent reverse stock splits) on the Nasdaq exchange. Since
February 2016, XWELL’s common stock has declined in value by
approximately 99%. As of July 23, 2024, XWELL’s stock closed at
approximately $1.85 per share.
Along with its staggering loss in market value,
XWELL has reported a combined net operating loss of $207.3 million
from 2018 through 2023. XWELL’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2023, discloses revenue decreased
from $55.9 million in 2022 to $30.1 million in 2023 and its
shareholder equity dropped from $39.9 million to $13 million in the
same period. XWELL is also burning through its cash, going from
cash and cash equivalents of more than $109.1 million in the third
quarter of 2021 to approximately $19.1 million in the first quarter
of 2024, and is failing to generate revenue that will slow its cash
depletion or return the Company to profitability. Our proposed
slate of directors is looking to heighten the focus on cost
efficiencies and controls, driving the core business towards
profitability and being cash flow positive.
The aforementioned failings of XWELL have come
during the reign of Chairman Bernstein, who has never worked in the
healthcare, medical, pharmaceutical or wellness industries; who has
no experience operating spas or wellness centers—XWELL’s core
businesses; and who has earned no degrees in business or the
natural sciences. Bernstein currently serves as a director for
several other public companies, and on average those entities have
lost 79.9% of their value since he joined their boards. Based on
available SEC filings, Bernstein has earned compensation in excess
of $2.3 million from those other public companies. Bernstein yields
significant control of XWELL, serving on every committee of the
XWELL Board and chairing all but one of them. Bernstein received
cash and stock valued at $1,605,554 million for his services to
XWELL and its affiliates in 2021 and $424,022 and $338,450 for his
services in 2022 and 2023, respectively. Berstein owns or has
options to purchase 1.9% of the issued and outstanding shares of
XWELL’s common stock.
The Entrenched Directors have not done anything
meaningful to reverse the near complete loss of XWELL’s value. For
example, under the reign of Chairman Bernstein, the Entrenched
Directors have: (i) failed to increase XWELL’s revenue streams or
decrease its costs such that the Company returns to profitability;
(ii) failed to explain to XWELL’s shareholders their strategic
plan, if any, to improve XWELL’s financial condition; (iii)
struggled to expand the Company from an airport-based studio model
to both an airport and off-airport based service model; and (iv)
regularly awarded and paid themselves large compensation packages
at the expense of shareholders.
Shareholders have not had an opportunity to
alter the strategic direction of XWELL; at every annual shareholder
meeting since 2016, candidates nominated by the Board have run
unopposed. On June 17, 2024, CPC sought to change this and
delivered to XWELL its director nomination notice, which nominated
four highly experienced individuals—the CPC Nominees—for election
to the Board at this year’s not yet scheduled annual shareholder
meeting. However, as noted above, the Entrenched Directors took
every measure to obstruct CPC’s efforts to nominate a competing
slate of directors for election at the annual shareholder
meeting.
CPC’s vision is clear:
- Position XWELL
for sustained shareholder value creation by replacing the current
Board of Directors with directors who will put the shareholders’
interests ahead of their own personal financial gain;
- Improve the
health of XWELL’s current business by containing cost and
eliminating non-profitable sites, services and products in order to
stop the existing cash burn and preserve cash on the balance sheet;
and
- Explore a
strategy to use the Company’s cash to acquire high-demand,
high-margin businesses with significant positive cash flow in the
health and wellness space.
XWELL shareholders deserve the opportunity to
elect directors to the Board who possess the leadership,
appropriate background and expertise needed to successfully
navigate a course to profitability; who bring knowledge and
integrity to the table; and whose dedication to creating
shareholder value eclipses a propensity for self-gain.
Sincerely,
Richard WaldoManaging Member, CPC Pain & Wellness SPV,
LLC
Contact: MZ North America ABETTERXWELL@mzgroup.us
XWELL (NASDAQ:XWEL)
Historical Stock Chart
From Oct 2024 to Nov 2024
XWELL (NASDAQ:XWEL)
Historical Stock Chart
From Nov 2023 to Nov 2024